Identifying Hub Genes for Chemo-radiotherapy Sensitivity in Cervical Cancer: a Bi-dataset in Silico Analysis

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2024 Sep 12

PMID 39264467

Authors

Yanhong Wang

Yi Ouyang

Xinping Cao

Qunrong Cai

Affiliations

Soon will be listed here.

Abstract

Purpose: To identify the hub genes that associated with chemo-radiotherapy sensitivity for cervical cancer and to explore the relationship between hub genes and various cellular processes and potential mechanism of cervical cancer.

Methods: The gene expression data of 21 patients with CESC and the mRNA expression profiles of 296 patients with CESC were obtained from the Gene Expression Omnibus(GEO) and The Cancer Genome Atlas (TCGA) databases, respectively. The potential functions and regulatory mechanisms of differentially expressed genes (DEGs) were identified using GO and KEGG enrichment analyses. Hub genes were identified using random survival forest analysis. The relationship between hub genes and various cellular processes was comprehensively analyzed. The expression of hub genes was assessed using clinical data extracted from the Human Protein Atlas (HPA) database.

Results: A total of 139 and 13 DEGs were found to be upregulated and downregulated, respectively, in CESC. The six hub genes, namely, SELP, PIM2, CCL19, SDS, NRP1, and SF3A2, were significantly correlated with immune cell infiltration, chemotherapy sensitivity, disease-related genes, and enriched signaling pathways (all p-value < 0.05). A nomogram and calibration curve were generated using the six hub genes to predict prognosis with high accuracy. A regulatory network comprising TFs (ZBTB3) and mRNAs (NRP1/PIM2/SELP) and several competitive endogenous RNA (ceRNA) networks comprising mRNAs, miRNAs, and lncRNAs were constructed. Data from HPA indicated that the protein expression of the six hub genes differed significantly between patients with CESC and healthy individuals.

Conclusion: Upregulation of SELP, PIM2, CCL19, SDS, NRP1, and SF3A2 is associated with radiotherapy sensitivity and is involved in various cellular processes in CESC. These six genes may serve as biomarkers for predicting the radiotherapy response and prognosis in patients with CESC.

References

Rose P, Bundy B, Watkins E, Thigpen J, Deppe G, Maiman M . Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340(15):1144-53. DOI: 10.1056/NEJM199904153401502. View

Rodrigues M, Vanoni G, Loap P, Dubot C, Timperi E, Minsat M . Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial. Nat Commun. 2023; 14(1):3698. PMC: 10287640. DOI: 10.1038/s41467-023-39383-8. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Dai J, Pan Y, Chen Y, Yao S . A panel of seven immune-related genes can serve as a good predictive biomarker for cervical squamous cell carcinoma. Front Genet. 2022; 13:1024508. PMC: 9667556. DOI: 10.3389/fgene.2022.1024508. View

Dong J, Gao H, Zuo S, Zhang H, Zhao G, Sun S . Neuropilin 1 expression correlates with the Radio-resistance of human non-small-cell lung cancer cells. J Cell Mol Med. 2015; 19(9):2286-95. PMC: 4568932. DOI: 10.1111/jcmm.12623. View

Jayakumar H, Seetharaman A, Sunder Singh S, Dhandapani H, Subramani J, Ganeshrajah S . Combination of IDO1 and CCL19 expression in the tumor tissue reduces survival in HPV positive cervical cancer. J Reprod Immunol. 2021; 149:103454. DOI: 10.1016/j.jri.2021.103454. View

Zhang J, Yu Y, Yin X, Feng L, Li Z, Liu X . A Circ-0007022/miR-338-3p/Neuropilin-1 Axis Reduces the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Activating Epithelial-To-Mesenchymal Transition and PI3K/AKT Pathway. Front Genet. 2022; 13:854097. PMC: 9100939. DOI: 10.3389/fgene.2022.854097. View

Jiang K, Ai Y, Li Y, Jia L . Nomogram models for the prognosis of cervical cancer: A SEER-based study. Front Oncol. 2022; 12:961678. PMC: 9583406. DOI: 10.3389/fonc.2022.961678. View

Zhu J, Chen S, Yang B, Mao W, Yang X, Cai J . Molecular mechanisms of lncRNAs in regulating cancer cell radiosensitivity. Biosci Rep. 2019; 39(8). PMC: 6712435. DOI: 10.1042/BSR20190590. View

10.

Eschrich S, Pramana J, Zhang H, Zhao H, Boulware D, Lee J . A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys. 2009; 75(2):489-96. PMC: 3038688. DOI: 10.1016/j.ijrobp.2009.06.014. View

11.

Xu T, Zeng Y, Shi L, Yang Q, Chen Y, Wu G . Targeting NEK2 impairs oncogenesis and radioresistance via inhibiting the Wnt1/β-catenin signaling pathway in cervical cancer. J Exp Clin Cancer Res. 2020; 39(1):183. PMC: 7488040. DOI: 10.1186/s13046-020-01659-y. View

12.

Shiao S, Coussens L . The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia. 2010; 15(4):411-21. PMC: 3011087. DOI: 10.1007/s10911-010-9194-9. View

13.

Jiang W, Ouyang X, Ji Z, Shi W, Wu Y, Yao Q . The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer. Cancer Lett. 2023; 556:216064. DOI: 10.1016/j.canlet.2023.216064. View

14.

Datta N, Stutz E, Liu M, Rogers S, Klingbiel D, Siebenhuner A . Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis. Gynecol Oncol. 2017; 145(2):374-385. DOI: 10.1016/j.ygyno.2017.01.033. View

15.

Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M . GeneCards Version 3: the human gene integrator. Database (Oxford). 2010; 2010:baq020. PMC: 2938269. DOI: 10.1093/database/baq020. View

16.

. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008; 26(35):5802-12. PMC: 2645100. DOI: 10.1200/JCO.2008.16.4368. View

17.

Huang R, Zhou P . DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020; 5(1):60. PMC: 7192953. DOI: 10.1038/s41392-020-0150-x. View

18.

Zhang Z, Guo Y, Qiu C, Deng G, Guo M . Protective Action of Se-Supplement Against Acute Alcoholism Is Regulated by Selenoprotein P (SelP) in the Liver. Biol Trace Elem Res. 2016; 175(2):375-387. DOI: 10.1007/s12011-016-0780-6. View

19.

Chan J, Tay Y . Noncoding RNA:RNA Regulatory Networks in Cancer. Int J Mol Sci. 2018; 19(5). PMC: 5983611. DOI: 10.3390/ijms19051310. View

20.

Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P . Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997; 350(9077):535-40. DOI: 10.1016/S0140-6736(97)02250-2. View